MOTS-c vs SS-31
Mitochondrial-derived exercise mimetic vs mitochondria-targeted antioxidant — two distinct peptide approaches to mitochondrial health and longevity research.
Last updated: 2026-03-08
Quick Comparison Table
| Category | MOTS-c | SS-31 |
|---|---|---|
| Origin | Mitochondrial genome (12S rRNA gene) | Synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe) |
| Primary Mechanism | AMPK activation, folate-methionine cycle modulation | Cardiolipin binding, electron transport chain stabilisation |
| Key Effect | Exercise mimetic, metabolic regulation | Mitochondrial membrane protection, ROS reduction |
| Administration | SC injection (research) | SC injection or IV (clinical trials) |
| Clinical Development | Preclinical/early translational | Phase II/III (Elamipretide/Stealth BioTherapeutics) |
| Longevity Link | AMPK-mediated metabolic rejuvenation | Mitochondrial membrane integrity preservation |
| Exercise Effect | Mimics exercise at molecular level | Enhances exercise capacity via mitochondrial efficiency |
| Approval Status | Investigational (no clinical trials) | Phase III for Barth syndrome; Phase II for other indications |
Mechanism of Action
MOTS-c
MOTS-c Mechanism:
MOTS-c (Mitochondrial Open-reading-frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded within the mitochondrial genome — one of the first identified mitochondrial-derived peptides (MDPs).
Key actions: 1. **AMPK activation** — Mimics the metabolic effects of exercise by activating AMP-activated protein kinase 2. **Folate cycle modulation** — Inhibits the folate-methionine cycle, altering cellular methylation 3. **Metabolic regulation** — Improves insulin sensitivity, glucose uptake, and fatty acid oxidation 4. **Nuclear translocation** — Under stress, MOTS-c translocates to the nucleus where it regulates gene expression (adaptive stress response)
MOTS-c levels decline with age, and its decline correlates with metabolic dysfunction. Exercise increases endogenous MOTS-c levels, supporting its characterisation as an "exercise mimetic."
SS-31
SS-31 (Elamipretide) Mechanism:
SS-31 is a synthetic cell-permeable tetrapeptide that selectively targets and concentrates in the inner mitochondrial membrane.
Key actions: 1. **Cardiolipin binding** — Stabilises cardiolipin, a critical phospholipid for cristae structure and ETC organisation 2. **Electron transport chain optimisation** — Improves Complex I-IV efficiency and ATP production 3. **ROS reduction** — Reduces mitochondrial superoxide production by optimising electron flow 4. **Cytochrome c interaction** — Prevents cytochrome c peroxidase activity that damages mitochondrial membranes 5. **Mitochondrial dynamics** — Promotes healthy fission/fusion balance
SS-31's unique feature is its selectivity for mitochondrial membranes — concentrating 1000-5000x in mitochondria vs cytoplasm. This targeting is driven by its alternating aromatic-cationic structure.
Clinical Trial Evidence
MOTS-c Clinical Studies
Participants: 0
Duration: 8 weeks
MOTS-c reversed age-related insulin resistance and improved glucose tolerance in old mice. Weight gain prevented.
Statistically significant
Participants: 0
Duration: 2 weeks
MOTS-c improved treadmill endurance by 50% in untrained mice, mimicking exercise training adaptations.
Statistically significant
Participants: 0
Duration: 12 weeks
MOTS-c prevented high-fat diet obesity. Treated mice maintained lean phenotype despite caloric excess.
Statistically significant
Participants: 500
Duration: Cross-sectional
Circulating MOTS-c levels decline ~30% between ages 20-70. Lower levels correlate with metabolic syndrome.
Statistically significant
Participants: 0
Duration: In vitro
Under metabolic stress, MOTS-c translocates to nucleus and regulates antioxidant gene expression (Nrf2 pathway).
Statistically significant
SS-31 Clinical Studies
Participants: 60
Duration: 168 weeks
Elamipretide improved 6-minute walk test and strength in Barth syndrome patients. Orphan drug fast track.
Statistically significant
Participants: 71
Duration: 4 weeks
SS-31 improved left ventricular end-systolic volume in HFrEF patients. Trend toward improved cardiac function.
Statistically significant
Participants: 40
Duration: 24 weeks
Elamipretide stabilised eGFR decline in patients with primary mitochondrial myopathy-associated kidney disease.
Statistically significant
Participants: 30
Duration: 5 days
Single-dose Elamipretide improved 6-minute walk test and perceived fatigue in mitochondrial myopathy.
Statistically significant
Participants: 0
Duration: 8 weeks
SS-31 reversed age-related diastolic dysfunction, improved cardiac reserve, and restored mitochondrial cristae density in old mice.
Statistically significant
Benefits Comparison
MOTS-c Unique Benefits
- Endogenous molecule (mitochondrial-derived)
- Exercise mimetic without physical exertion
- AMPK activation — master metabolic regulator
- Anti-obesity effects in preclinical models
- Declines with age (replacement rationale)
Shared Benefits
- Mitochondrial health improvement
- Potential longevity/anti-ageing applications
- Improved metabolic function
- Age-related decline relevance
- ROS/oxidative stress reduction
SS-31 Unique Benefits
- Advanced clinical pipeline (Phase II/III)
- Selective mitochondrial targeting (1000-5000x concentration)
- Structural mitochondrial membrane repair
- Multiple clinical indications under investigation
- Rapid onset of mitochondrial function improvement
Research & Evidence
MOTS-c Research
MOTS-c research is primarily from the Cohen laboratory (USC). Evidence is exclusively preclinical — mouse models and cell culture. The correlation between declining MOTS-c levels and ageing/metabolic syndrome in humans is established, but no exogenous MOTS-c has been tested in human clinical trials.
SS-31 Research
SS-31/Elamipretide has been studied in 500+ patients across multiple Phase II/III trials by Stealth BioTherapeutics. It has orphan drug designations for Barth syndrome and mitochondrial myopathy. The clinical evidence base is substantially more mature than MOTS-c, though full regulatory approval has not yet been achieved.
Head-to-Head Analysis
Direct Comparison:
No head-to-head trial exists.
Complementary Mechanisms: MOTS-c works "from the mitochondrial genome out" — a signalling peptide that activates metabolic pathways (AMPK) mimicking exercise. SS-31 works "from outside in" — a synthetic peptide that physically stabilises mitochondrial membranes and electron transport.
Research Maturity: SS-31 is significantly more advanced clinically — Phase II/III trials for Barth syndrome, heart failure, renal disease, and mitochondrial myopathy. MOTS-c is primarily preclinical with no human clinical trials yet.
Longevity Angle: Both address mitochondrial dysfunction — a central hallmark of ageing. MOTS-c approaches it through metabolic signalling; SS-31 through structural membrane preservation. They may be mechanistically complementary.
Protocol Comparison
MOTS-c Protocol
MOTS-c Theoretical Protocols (Research-Based):
Dosing: Mouse studies used 5mg/kg IP injection. Human equivalent doses are extrapolated but not clinically validated. Common research community doses: 5-10mg SC daily or 3x weekly.
Routes: SC injection (reconstituted from lyophilised powder).
Duration: Mouse studies: 2-12 weeks. Optimal human protocol unknown.
⚠️ Disclaimer: No human clinical trials exist for MOTS-c.
SS-31 Protocol
SS-31 (Elamipretide) Clinical Protocols:
Barth Syndrome (TAZPOWER): 40mg SC daily — long-term treatment.
Heart Failure (PROGRESS-HF): 4mg/hr IV infusion x 4 hours or 40mg SC daily.
Mitochondrial Myopathy: 40mg SC daily — duration varies by study.
Routes: SC injection (primary) or IV infusion (acute settings).
⚠️ Note: Investigational drug. Available through clinical trials only.
Safety Profiles
MOTS-c Safety
MOTS-c Safety:
No human safety data. Mouse studies show no adverse effects at 5mg/kg doses. As an endogenous peptide, theoretical safety profile is favourable, but exogenous administration at supraphysiological doses has not been evaluated in humans.
SS-31 Safety
SS-31 (Elamipretide) Safety:
Well-tolerated in 500+ patients across clinical trials. Most common side effect: injection site reactions (mild).
No serious drug-related adverse events in Phase II/III studies. Cardiac safety monitoring in HF trials showed no arrhythmia or QT prolongation concerns.
Long-term safety (168 weeks) established in Barth syndrome trial.
The Verdict
SS-31/Elamipretide is significantly more advanced clinically, with Phase II/III data across multiple indications and a well-characterised safety profile. MOTS-c is a fascinating endogenous peptide with compelling preclinical exercise-mimetic and anti-ageing data, but remains years from clinical translation. For mitochondrial disease, SS-31 is the research standard. For longevity and metabolic optimisation research, MOTS-c's unique position as an endogenous mitochondrial signal peptide makes it conceptually compelling. They address different aspects of mitochondrial health and may be complementary.
Frequently Asked Questions
Conclusion
MOTS-c and SS-31 represent two complementary approaches to mitochondrial health — endogenous metabolic signalling vs synthetic structural repair. SS-31 leads in clinical development with Phase II/III trials showing measurable improvements in mitochondrial disease. MOTS-c's identity as an endogenous exercise-mimetic peptide that declines with age positions it uniquely in longevity research, but clinical translation is still pending. Together, they illustrate the growing recognition that mitochondrial dysfunction is a druggable target for ageing and disease.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither MOTS-c nor SS-31 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.